Form 20-F/A BioNTech SE For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- US futures steady as oil retreats ahead of earnings deluge, Fed decision
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Oil slips but stays near six-month highs on Saudi attacks
Tweet
Share
E-mailhttp://archive.fast-edgar.com/20260730/AQVZC22CZ22FB2Z2222B22ZNGDQDZZ229Y82
Filed on: July 30, 2026
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioNTech and DualityBio report modest Phase 3 results for breast cancer drug
- BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
- BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
